168 related articles for article (PubMed ID: 37789619)
1. Immune checkpoint therapy in colorectal cancer: is first better than last?
Kaneko Y; Naseem Z; Strugnell N; Barnett F; D'Souza B; Sidhu A; Bui A; Pham T
Ann Coloproctol; 2023 Oct; 39(5):439-441. PubMed ID: 37789619
[No Abstract] [Full Text] [Related]
2. Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer.
Ding Y; Wang Z; Zhou F; Chen C; Qin Y
Front Oncol; 2022; 12():987302. PubMed ID: 36248998
[TBL] [Abstract][Full Text] [Related]
3. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer.
Oshima K; Yamazaki K
Int J Clin Oncol; 2023 Nov; 28(11):1442-1450. PubMed ID: 37668816
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis.
Zeng T; Fang X; Lu J; Zhong Y; Lin X; Lin Z; Wang N; Jiang J; Lin S
Int J Colorectal Dis; 2022 Jan; 37(1):251-258. PubMed ID: 34716473
[TBL] [Abstract][Full Text] [Related]
6. [Immune checkpoint inhibitors in the treatment of colorectal cancer: a review of clinical trials].
Gong XL; Zhao L
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):205-213. PubMed ID: 35340169
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.
Han K; Tang JH; Liao LE; Jiang W; Sui QQ; Xiao BY; Li WR; Hong ZG; Li Y; Kong LH; Li DD; Zhang XS; Pan ZZ; Steele SR; Ding PR
Dis Colon Rectum; 2023 Oct; 66(10):e996-e1005. PubMed ID: 35485833
[TBL] [Abstract][Full Text] [Related]
8. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
9. Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.
Gorzo A; Galos D; Volovat SR; Lungulescu CV; Burz C; Sur D
Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207516
[TBL] [Abstract][Full Text] [Related]
10. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
[TBL] [Abstract][Full Text] [Related]
11. The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
Tong H; Wei H; Smith AO; Huang J
Front Immunol; 2021; 12():802049. PubMed ID: 35069586
[TBL] [Abstract][Full Text] [Related]
12. Docosahexaenoic acid may inhibit immune evasion of colorectal cancer cells through targeting immune checkpoint and immunomodulator genes and their controlling microRNAs.
Fadaee M; Abbasi H; Maralbashi S; Baradaran B; Shanehbandi D; Dinevari MF; Kazemi T
Biofactors; 2022 Sep; 48(5):1137-1144. PubMed ID: 35533068
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers.
Zhong J; Sun Z; Li S; Yang L; Cao Y; Bao J
Discov Oncol; 2023 Jun; 14(1):94. PubMed ID: 37302081
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer.
Ephraim R; Feehan J; Fraser S; Nurgali K; Apostolopoulos V
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551617
[TBL] [Abstract][Full Text] [Related]
16. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
17. Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al.
Deming DA
J Immunother Cancer; 2016; 4():93. PubMed ID: 28031821
[TBL] [Abstract][Full Text] [Related]
18. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.
Liang T; Tong W; Ma S; Chang P
Oncoimmunology; 2020 Jun; 9(1):1773205. PubMed ID: 32934878
[TBL] [Abstract][Full Text] [Related]
19. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
[TBL] [Abstract][Full Text] [Related]
20. Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer.
Ros J; Balconi F; Baraibar I; Saoudi Gonzalez N; Salva F; Tabernero J; Elez E
Front Oncol; 2023; 13():1112276. PubMed ID: 36816981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
